Nonclinical Safety Evaluation of GalNAc-siRNA Conjugates

Nonclinical Safety Evaluation of GalNAc-siRNA Conjugates

We presented a nonclinical safety evaluation of GalNAc-siRNA conjugates at the 8th Annual Biologics Symposium, being held May 8-9, 2018 in Plainsboro, NJ.

View the presentation

These comprehensive nonclinical studies highlight the favorable tolerability profile and wide therapeutic margins for Alnylam’s GalNAc-siRNA conjugate platform.



SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.